Interleukin-10 (IL-10)- Pipeline Market and Global Major key Players Analysis

Interleukin-10 (IL-10)-Pipeline Review Information, by product (AM-0010, ANV-103, AS-101, BT-063, DEKAVIL / F8 IL10, EG-12, LEO-32731, MK-1966, PD-2244, XT-101, XT-150, therapies and others)

Interleukin-10 is an anti-inflammatory cytokines. Interleukin 10 helps to reduce the inflammation of immune cells by blocking the production of cytokines. They help to reduce the inflammation of immune cells by blocking the production of cytokines. Interleukin 10 (IL10) pipeline targets close to 2o molecules which are developed by Companies and the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 2 and 9 respectively.  

Request for sample report at https://www.marketresearchfuture.com/sample_request/2640 .

Study Objectives Interleukin-10 (IL-10) – Pipeline Review:

  • It provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
  • It reviews Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • It features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The key players involved in Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report reviews latest news and deals related to Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics.

Intended Audience

  • Companies with Interleukin-10 products
  • Government Research Laboratories
  • Academic Universities/Institutes
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Medical Research Laboratories

Key Finding

  • The Interleukin-10 (IL-10) – Pipeline Review 18 products are in pipeline
  • 9 products are in preclinical trials, 4 in phase II, 2 in phase I and 2 studies are discontinued due to tolerance issues

Browse Complete Report at https://www.marketresearchfuture.com/reports/interleukin-market .

Key Players for Interleukin-10 (IL-10) – Pipeline Review:

Some of the key players in this market are: Pfizer Inc.,

  • Merck & Co., Inc
  • Biotest AG
  • BioMAS Ltd
  • EnGene Inc.
  • Leo Pharma
  • Anvil Biosciences
  • Intrexon Corporation
  • P2D Biosciences
  • Xalud Therapeutics INC

Segments:

Interleukin-10 (IL-10) – Pipeline Review report has been segmented on the basis of product type which comprises of AM-0010, ANV-103, AS-101, BT-063, DEKAVIL / F8 IL10, EG-12, LEO-32731, MK-1966, PD-2244, XT-101, XT-150, therapies and others

The report for Interleukin-10 (IL-10) – Pipeline Review of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

Get a discount at https://www.marketresearchfuture.com/check-discount/2640 .

Table of Contents

1    Report Prologue    

2    Introduction    

2.1    Definition    

2.2    Scope of the Study    

2.2.1    Research Methodology    

2.2.2    Assumptions    

2.3    Limitations    

2.4    Market Structure    

3    Research Methodology    

3.1    Research Process    

3.2    Primary Research    

3.3    Secondary Research    

4    Market Dynamics    

4.1    Introduction    

4.2    Drivers    

4.2.1    Rising Launch of New Concepts By Key Manufacturers    

4.2.2    Larger Patient Base    

4.3    Restraints    

4.3.1    Stringent Regulatory Guidelines for the Use of The Drugs    

4.4    Mega Trends    

4.4.1    Development of New Technology for the Treatment of Disease    

4.4.2    Macroeconomic Indicators    

5    Market Factor Analysis    

5.1    Value Chain Analysis    

6    Stages of Clinical Trials    

6.1    Preclinical Trial    

6.2    Phase I Clinical Trial    

6.3    Phase II Clinical Trial    

6.4    Phase III Clinical Trial    

6.5    Phase IV Clinical Trial    

7    Interleukin 10 Pipeline Product Analysis, By Product    

7.1    AM-0010    

7.1.1    Product Description    

7.1.2    Mechanism of Action    

7.1.3    Clinical Trial Progress    

7.2    ANV-103    

7.2.1    Product Description    

7.2.2    Mechanism of Action    

7.2.3    Clinical Trial Progress    

7.3    AS-101    

7.3.1    Product Description    

7.3.2    Mechanism of Action    

7.3.3    Clinical Trial Progress    

7.4    BT-063    

7.4.1    Product Description    

7.4.2    Mechanism of Action    

7.4.3    Clinical Trial Progress    

7.5    DEKAVIL/F8 IL10    

7.5.1    Product Description    

7.5.2    Mechanism of Action    

7.5.3    Clinical Trial Progress    

7.6    EG-12    

7.6.1    Product Description    

7.6.2    Mechanism of Action    

7.6.3    Clinical Trial Progress    

7.7    LEO-32731    

7.7.1    Product Description    

7.7.2    Mechanism of Action    

7.7.3    Clinical Trial Progress    

7.8    MK-1966    

7.8.1    Product Description    

7.8.2    Mechanism of Action    

7.8.3    Clinical Trial Progress    

7.9    PD-2244    

7.9.1    Product Description    

7.9.2    Mechanism of Action    

7.9.3    Clinical Trial Progress    

7.10    XT-101    

7.10.1    Product Description    

7.10.2    Mechanism of Action    

7.10.3    Clinical Trial Progress    

7.11    XT-150    

7.11.1    Product Description    

7.11.2    Mechanism of Action    

7.11.3    Clinical Trial Progress    

7.12    Gene Therapy to Activate Interleukin 10 for Atherosclerosis    

7.12.1    Product Description    

7.12.2    Clinical Trial Progress    

7.13    Gene Therapy to Activate Interleukin-10 for ALS    

7.13.1    Clinical Trial Progress    

7.14    Biologic to Activate Glutamic Acid Decarboxylase and IL-10 for Type 1 Diabetes    

7.14.1    Clinical Trial Progress    

7.15    Biologic to Target Gluten and IL-10 for Celiac Disease    

7.15.1    Clinical Trial Progress    

7.16    Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation    

7.16.1    Clinical Trial Progress    

7.17    Synthetic Peptides to Inhibit IL-10 and IFN Gamma for Cancer, Viral Infections and Inflammatory Diseases    

7.17.1    Clinical Trial Progress    

8    COMPETITIVE LANDSCAPE    

8.1    ACQUISITIONS & PARTNERSHIP    

8.1.1    Pfizer Acquire Anacor    

8.1.2    Merck Aquire IOmet    

8.1.3    Takeda and EnGene Establish Strategic Alliance    

9    Company Profile    

9.1        

9.1.1    Overview    

9.1.2    Product Overview    

9.1.3    Financials    

9.1.4    Key Developments    

9.2    Merck & Co., Inc.    

9.2.1    Overview    

9.2.2    Product Overview    

9.2.3    Financials    

9.2.4    Key Developments    

9.3    Biotest AG    

9.3.1    Overview    

9.3.2    Product Overview    

9.3.3    Financials    

9.3.4    Key Developments    

9.4    BioMAS Ltd.    

9.4.1    Overview    

9.4.2    Product Overview    

9.4.3    Key Development    

9.5    EnGene Inc.    

9.5.1    Overview    

9.5.2    Product Overview    

9.5.3    Key Developments    

9.6    Leo Pharma    

9.6.1    Overview    

9.6.2    Product Overview    

9.6.3    Financials    

9.6.4    Key Developments    

9.7    Anvil Biosciences    

9.7.1    Overview    

9.7.2    Product Overview    

9.7.3    Financials    

9.8    Intrexon Corporation    

9.8.1    Overview    

9.8.2    Product Overview    

9.8.3    Financials    

9.8.4    Key Developments    

9.9    P2D Biosciences    

9.9.1    Overview    

9.9.2    Product Overview    

9.9.3    Key Developments    

9.10    Xalud Therapeutics INC.    

9.10.1    Overview    

9.10.2    Product Overview    

9.10.3    Key Developments    

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Email: akash.anand@marketresearchfuture.com
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/interleukin-market